M Holdings Securities Inc. Makes New $5.20 Million Investment in AbbVie Inc. $ABBV

M Holdings Securities Inc. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 22,771 shares of the company’s stock, valued at approximately $5,203,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after purchasing an additional 448,554 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of AbbVie by 17.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock valued at $241,888,000 after purchasing an additional 151,644 shares during the period. Thornburg Investment Management Inc. increased its holdings in shares of AbbVie by 25.5% in the 3rd quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company’s stock valued at $93,024,000 after purchasing an additional 81,625 shares during the period. Channing Capital Management LLC increased its holdings in shares of AbbVie by 10.5% in the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company’s stock valued at $12,885,000 after purchasing an additional 5,302 shares during the period. Finally, Procyon Advisors LLC increased its holdings in shares of AbbVie by 19.9% in the 4th quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock valued at $7,484,000 after purchasing an additional 5,427 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABBV. Cantor Fitzgerald reiterated an “overweight” rating and issued a $240.00 target price on shares of AbbVie in a report on Thursday, April 30th. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Morgan Stanley raised their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Stock Performance

Shares of ABBV opened at $225.16 on Thursday. The firm has a market cap of $397.82 billion, a PE ratio of 110.92, a PEG ratio of 0.69 and a beta of 0.32. The firm’s 50 day moving average price is $210.64 and its 200 day moving average price is $219.09. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.